Jaysingh Singh, MD
Epilepsy · Columbus, OHNPI 1538424973
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by UCB SA at 46.6% of the total.
Across 18 payments — averaging $171.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$1K
- DIXI Medical USA Corp$833
- Medtronic$799
- Catalyst Pharmaceuticals, Inc.$17
Across 32 payments — averaging $7773.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$163K
- Medtronic$77K
- AbbVie$9K
What the payments were for
- Travel & lodging$1,58651%
- Food & beverage$1,48748%
- Education$171%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 10 | $1,441 |
| DIXI Medical USA Corp | 1 | $833 |
| Medtronic | 6 | $799 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,090 in reported general payments places this provider in the 80th percentile of 21 epilepsy providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 45 | $80,110 |
| AptiomEslicarbazepine Acetate | 37 | $71,768 |
| OnfiClobazam | 12 | $48,949 |
| LamictalLamotrigine | 27 | $44,086 |
| FycompaPerampanel | 28 | $35,034 |
| Oxtellar XrOxcarbazepine | 23 | $27,215 |
| Lacosamide | 144 | $18,991 |
| NayzilamMidazolam | 18 | $18,903 |
| VimpatLacosamide | 13 | $17,064 |
| Clobazam | 80 | $12,515 |
| Levetiracetam | 238 | $10,434 |
| Lamotrigine ErLamotrigine | 15 | $6,797 |
| Levetiracetam ErLevetiracetam | 37 | $4,612 |
| Oxcarbazepine | 70 | $3,777 |
| Divalproex Sodium ErDivalproex Sodium | 47 | $3,644 |
Paid to pharmacies, not to this prescriber.
Other epilepsy in Columbus
- Danielle BeckerColumbus$1.6M
- Jason BispingColumbus$261K
- Emily KlatteColumbus$64K
- Bryan BergerColumbus$1K
- Angela ParsonsColumbus$484
- Sarita MaturuColumbus$280
- Nabil KhandkerColumbus$156
- Mohamad RahwanWest Chester$7K
- Neel FotedarCleveland$3K
- Luisa Londono-HurtadoCleveland$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.